Guggenheim Downgrades Revance Therapeutics(RVNC.US) to Hold Rating, Cuts Target Price to $6.66
Guggenheim analyst Vamil Divan downgrades $Revance Therapeutics(RVNC.US)$ to a hold rating, and adjusts the target price from $30 to $6.66.According to TipRanks data, the analyst has a success rate
Crown Labs Tender Offer for Revance Delayed, Expect Deal to Be Completed - Analyst
Revance Therapeutics Falls as Crown Labs Didn't Start Tender Offer by Deadline
Barclays Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Maintains Target Price $7
Barclays analyst Balaji Prasad maintains $Revance Therapeutics(RVNC.US)$ with a hold rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 48.0%
Revance Therapeutics Analyst Ratings
Barclays Downgrades Revance Therapeutics to Equalweight From Overweight, Price Target Is $7